SCHEMBL264716

SCHEMBL264716

CC1CCCCN1S(=O)(=O)c1cccc(Br)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 1/20 0.58
▸ PSEN2 P49810 1/20 0.58
▸ APH1B Q8WW43 1/20 0.58
▸ NCSTN Q92542 1/20 0.58
▸ APH1A Q96BI3 1/20 0.58
▸ PSENEN Q9NZ42 1/20 0.58
▸ HTR7 P34969 2/20 0.58
▸ HTR1A P08908 1/20 0.58
▸ DRD2 P14416 1/20 0.58
▸ HTR1D P28221 1/20 0.58
▸ HTR1B P28222 1/20 0.58
▸ DRD3 P35462 1/20 0.58
▸ HTR6 P50406 1/20 0.58
▸ MBTD1 Q05BQ5 1/20 0.56
▸ L3MBTL3 Q96JM7 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ KMT2A Q03164 1/20 0.52
▸ AKR1C3 P42330 8/20 0.51
▸ LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15276781 0.82 SIRT2 (0.69) ALDH1A1KMT2AAKR1C3HCRTR1HCRTR2
SCHEMBL14547463 0.82 PSEN1 (0.73) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18707204 0.81 HTR7 (0.67) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2305949 0.80 HSD11B1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1369545 0.80 PSEN1 (0.60) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL16169927 0.79 PSEN1 (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4563889 0.78 PRKACA (0.49) HTR7HTR1ADRD2HTR1DHTR1B
SCHEMBL18065225 0.78 PSEN1 (0.66) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL264934 0.78 ACHE (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18065224 0.78 PSEN1 (0.66) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951684-B1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN INC (US) 2016-07-13 — — EP disclosed
US-8604042-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2013-12-10 — — US disclosed
CN-101370792-B Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN INC 2013-03-20 — — CN disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 — — US disclosed
US-8133900-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-13 — — US disclosed
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-09-01 — — US disclosed
US-7825246-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2010-11-02 — — US disclosed
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases TARGEGEN, INC. (US) 2009-11-19 — — US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
CN-101370792-A Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN INC (US) 2009-02-18 — — CN disclosed
EP-1951684-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES Targegen, Inc. (US) 2008-08-06 — — EP disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
WO-2007053452-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, LTK PSEN1 4591/4885PSEN2 4259/4885APH1B 4533/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 PSEN1 4741/4885PSEN2 4480/4885APH1B 4342/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 PSEN1 4741/4885PSEN2 4480/4885APH1B 4342/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 PSEN1 4741/4885PSEN2 4480/4885APH1B 4342/4885
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES JAK2, TYK2, JAK3 PSEN1 4741/4885PSEN2 4480/4885APH1B 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback